NCT00210314View on ClinicalTrials.gov

Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

September 30, 2007

Study Completion Date

December 31, 2007

Conditions
Lymphoma, B Cell
Interventions
DRUG

high dose methotrexate

DRUG

high dose cytarabine

RADIATION

radiotherapy

Trial Locations (1)

6500

Oncology Institute of Southern Switzerland (IOSI), Bellinzona

All Listed Sponsors
lead

International Extranodal Lymphoma Study Group (IELSG)

OTHER

NCT00210314 - Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma | Biotech Hunter | Biotech Hunter